STEM appoints Dermot Kenny as new CEO

Leading global pharmaceutical and life sciences auditing firm, STEM, an Inizio Advisory company, has appointed Dermot Kenny as its new CEO.

Dermot has extensive experience in the pharmaceutical industry spanning over 25 years. His most recent role was leading Novartis’ Global Clinical Technology and Innovation team.

Throughout his career, he has successfully led large global teams, built large-scale custom client solutions, implemented various clinical development platforms and driven organizational transformation.

At STEM, Dermot will be responsible for driving growth, diversifying the company’s offering and expanding its geographic reach and global presence.

STEM partners with clients to evaluate and improve field team performance, using a one-of-a-kind benchmark database that includes more than 500,000 in-field observations completed across 59 countries.

Speaking about his appointment, Dermot commented: “It’s a privilege to join STEM at such a pivotal time for the industry and in the company’s journey. STEM has an exceptional reputation and works with many of the leading companies in the Pharma and Biotech sectors to help enhance their performance at a time when the market is becoming increasingly complex and competitive.

“Our success has been built on the quality of STEM’s people, their credibility and ability to engage productively with both local and global functions. I’m very excited to be leading the next phase of STEM’s growth.”

STEM quantifies and benchmarks strategic alignment from leadership direction to field execution, working with clients to pinpoint strengths and create opportunities to improve performance across Commercial, Medical, Access and First-Line Manager teams.

An Inizio Advisory company, STEM works alongside Vynamic, Putnam Associates and SmartAnalyst, combining their expertise to provide integrated services to customers.